ClinicalTrials.gg
RecruitingNCT07218783Updated Oct 20, 2025

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)

A Phase 3 interventional study of Bimatoprost Implant System and SpyGlass IOL in Cataract, Glaucoma and Ocular Hypertension, sponsored by SpyGlass Pharma, Inc.. Recruiting at 1 site in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2025-10-20.

Sponsored by SpyGlass Pharma, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 456 studies in Cataract with a site in United States — 49 open to participants now, 56 under way, 4 of them phase 3. Cataract · United States.

Planned enrollment
44th of 322
400 · median 100
Started
2025
with 23 others
Phase 3
57 of 456
4 open now
Primary completion
2029-03
later than 51 of 54 live
Registered
423rd of 456
by date

Among the 456 studies in Cataract with a site in United States, this one is the 44th largest by planned enrollment of the 322 interventional ones that give a count, is one of 24 that started in 2025, is one of 57 in phase 3, reaches primary completion later than 51 of the 54 other live ones, and was the 423rd registered.

Cataract

1,632 studies on the registry are indexed under Cataract; 235 are open to participants now.

Browse Cataract studies →

Open to participants now

49 of the 456 studies in Cataract with a site in United States are open now. Recruiting first, the newest first:

43 more — sign in →

All 49 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 142 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 456 studies in Cataract with a site in United States, or all of them as a file.
02

Study summary

This trial is a randomized study to evaluate the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery.

03

Conditions studied

  • Cataract
  • Glaucoma
  • Ocular Hypertension
04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of mild to moderate open-angle glaucoma or ocular hypertension
  • Planned removal of cataract
  • Female participants of must have a negative urine pregnancy test at the baseline visit and agree to the use of

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled systemic disease
  • History of incisional/refractive corneal surgery
  • Any glaucoma diagnosis other than OHT, open-angle, pseudoexfoliative, or pigmentary glaucoma
  • History of incisional glaucoma surgery or intraocular injections
  • Other ocular diseases, pathology, or conditions
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Bimatoprost Implant System / IOL Combination

    Drug: Bimatoprost Implant System · Device: SpyGlass IOL

  • Active comparator
    Timolol Maleate Ophthalmic Solution 0.5%

    Drug: Timolol Maleate Ophthalmic Solution, 0.5% · Device: Commercial IOL

Interventions

  • DrugBimatoprost Implant System

    Bimatoprost Implant System used in combination with the SpyGlass IOL

  • DeviceSpyGlass IOL

    SpyGlass Intraocular Lens

  • Timolol Maleate Ophthalmic Solution, 0.5% BID

  • DeviceCommercial IOL

    Commercially Available Aspheric Monofocal Non-Yellow Chromophore Intraocular Lens

06

What researchers measure

Primary outcomes

  1. Mean IOP Reduction from Baseline (mmHg)

    Time-matched mean IOP change from Baseline in the study eyes at all the individual IOP timepoints

    Time frame: Weeks 2 and 6, and Month 3

  2. BCDVA 20/40 or better

    Study eyes achieving best corrected distance visual acuity (BCDVA) of 20/40 or better

    Time frame: Month 6

Secondary outcomes

  1. Mean IOP Reduction from Baseline (mmHg)

    Time matched mean IOP reduction from Baseline (mmHg) in the study eyes at all the individual IOP timepoints

    Time frame: Month 6, 9 and 12

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Mar 2029, 41 months after the start.

Of 23 industry-sponsored phase 3 interventional studies under Cataract, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 15. This study's planned 41 months is above that.

Counting every sponsor, half of 31 studies reached it within 13 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2025
First posted
Oct 20, 2025
StartActual
Oct 15, 2025
Primary completionEst.
Mar 31, 2029
CompletionEst.
Mar 31, 2031
Last update
Oct 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07218783
Lead sponsor
SpyGlass Pharma, Inc.
Responsible party
Sponsor
First posted
Oct 20, 2025
Start date
Oct 15, 2025
Primary completion
Mar 31, 2029 (estimated)
Completion
Mar 31, 2031 (estimated)
Last update
Oct 20, 2025

Study contacts

Director, Clinical Affairs
Contact
clinical@spyglasspharma.com
949-284-6904
Paul Yoo, OD
study chair · SpyGlass Pharma

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion